ES2289573T3 - Uso de 3-aza-1-oxa-dibenzo(e,h)azulenos para la fabricacion de formulaciones farmaceuticas para el tratamiento y la prevencion de enfermedades y trastornos del sistema nervioso central. - Google Patents

Uso de 3-aza-1-oxa-dibenzo(e,h)azulenos para la fabricacion de formulaciones farmaceuticas para el tratamiento y la prevencion de enfermedades y trastornos del sistema nervioso central. Download PDF

Info

Publication number
ES2289573T3
ES2289573T3 ES04798733T ES04798733T ES2289573T3 ES 2289573 T3 ES2289573 T3 ES 2289573T3 ES 04798733 T ES04798733 T ES 04798733T ES 04798733 T ES04798733 T ES 04798733T ES 2289573 T3 ES2289573 T3 ES 2289573T3
Authority
ES
Spain
Prior art keywords
dibenzo
aza
alkyl
oxa
azulen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES04798733T
Other languages
English (en)
Spanish (es)
Inventor
Mladen Mercep
Milan Mesic
Dijana Pesic
Iva Dzapo
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Fidelta doo
Original Assignee
GlaxoSmithKline Istrazivacki Centar Zagreb doo
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by GlaxoSmithKline Istrazivacki Centar Zagreb doo filed Critical GlaxoSmithKline Istrazivacki Centar Zagreb doo
Application granted granted Critical
Publication of ES2289573T3 publication Critical patent/ES2289573T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/424—Oxazoles condensed with heterocyclic ring systems, e.g. clavulanic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Pain & Pain Management (AREA)
  • Child & Adolescent Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Addiction (AREA)
  • Endocrinology (AREA)
  • Anesthesiology (AREA)
  • Reproductive Health (AREA)
  • Obesity (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
ES04798733T 2003-11-21 2004-11-19 Uso de 3-aza-1-oxa-dibenzo(e,h)azulenos para la fabricacion de formulaciones farmaceuticas para el tratamiento y la prevencion de enfermedades y trastornos del sistema nervioso central. Expired - Lifetime ES2289573T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
HR20030959A HRP20030959A2 (en, 2012) 2003-11-21 2003-11-21
HR20030959 2003-11-21

Publications (1)

Publication Number Publication Date
ES2289573T3 true ES2289573T3 (es) 2008-02-01

Family

ID=34611163

Family Applications (1)

Application Number Title Priority Date Filing Date
ES04798733T Expired - Lifetime ES2289573T3 (es) 2003-11-21 2004-11-19 Uso de 3-aza-1-oxa-dibenzo(e,h)azulenos para la fabricacion de formulaciones farmaceuticas para el tratamiento y la prevencion de enfermedades y trastornos del sistema nervioso central.

Country Status (10)

Country Link
US (1) US20070111990A1 (en, 2012)
EP (1) EP1684766B1 (en, 2012)
JP (1) JP2007512308A (en, 2012)
CN (1) CN1901918A (en, 2012)
AT (1) ATE365556T1 (en, 2012)
CA (1) CA2546591A1 (en, 2012)
DE (1) DE602004007289T2 (en, 2012)
ES (1) ES2289573T3 (en, 2012)
HR (1) HRP20030959A2 (en, 2012)
WO (1) WO2005049036A1 (en, 2012)

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3711489A (en) * 1971-03-31 1973-01-16 Pfizer Certain 8,9-dihydro(3,4,7,8)cycloocta(1,2-d)imidazoles
NL7605526A (nl) * 1976-05-24 1977-11-28 Akzo Nv Nieuwe tetracyclische derivaten.
US4198421A (en) * 1978-11-30 1980-04-15 E. I. Du Pont De Nemours And Company Antiinflammatory 2-substituted-dibenzo[2,3:6,7]oxepino[4,5-d]imidazoles
FR2504140A1 (fr) * 1981-04-16 1982-10-22 Centre Nat Rech Scient Nouveaux derives tetracycliques de la dibenzazepine, leur procede de preparation et les compositions pharmaceutiques en renfermant
US4666716A (en) * 1984-09-04 1987-05-19 Richardson-Vicks Inc. Antidiarrheal compositions and use thereof
DK0510068T3 (da) * 1990-01-11 1999-10-25 Upjohn Co Nye 6,7,8,9-tetrahydro-3H-benz(e)indol-heterocycler med virkning på centralnervesystemet
UA52778C2 (uk) * 1997-10-10 2003-01-15 Янссен Фармацевтика Н.В. Галогенозаміщені тетрациклічні похідні тетрагідрофурану, спосіб їх отримання та композиція на їх основі
US6015557A (en) * 1999-02-24 2000-01-18 Tobinick; Edward L. Tumor necrosis factor antagonists for the treatment of neurological disorders
HRP20020304B1 (en) * 2002-04-10 2008-04-30 GlaxoSmithKline istra�iva�ki centar Zagreb d.o.o. 1-oxa-3-aza-dibenzoazulenes as inhibitors of tumor necrosis factor production and intermediates for the production thereof

Also Published As

Publication number Publication date
DE602004007289T2 (de) 2008-03-06
HRP20030959A2 (en, 2012) 2005-10-31
WO2005049036A1 (en) 2005-06-02
DE602004007289D1 (de) 2007-08-09
JP2007512308A (ja) 2007-05-17
EP1684766A1 (en) 2006-08-02
EP1684766B1 (en) 2007-06-27
ATE365556T1 (de) 2007-07-15
CA2546591A1 (en) 2005-06-02
US20070111990A1 (en) 2007-05-17
HK1098670A1 (en) 2007-07-27
CN1901918A (zh) 2007-01-24

Similar Documents

Publication Publication Date Title
US20060241099A1 (en) Use of 2-thia-dibenzo[e,h]azulenes for the manufacture of pharmaceutical formulations for the treatment and prevention of central nervous system diseases and disorders
ES2289573T3 (es) Uso de 3-aza-1-oxa-dibenzo(e,h)azulenos para la fabricacion de formulaciones farmaceuticas para el tratamiento y la prevencion de enfermedades y trastornos del sistema nervioso central.
ES2320000T3 (es) Uso de 1-oxadibenzo(e,h)azulenos para la fabricacion de formulaciones farmaceuticas para el tratamiento y la prevencion de enfermedades y trastornos del sistema nervioso central.
ES2320229T3 (es) Uso de 1,2-diaza-dibenzo(e,h)azulenos para la fabricacion de formulaciones farmaceuticas para el tratamiento y la prevencion de enfermedades y trastornos del sistema nervioso central.
ES2291960T3 (es) Uso de 1-tia-dibenzo-e,h-azulenos para la fabricacion de formulaciones farmaceuticas para el tratamiento y la prevencion de enfermedades y trrantorno del sistema nervioso central.
ES2319904T3 (es) Preparacion de 1-aza-2-oxa-dibenzo (e,h) azulenos u su uso para la fabricacion de formulaciones farmaceuticas para el tratamiento y la prevencion de enfermedades y trastornos del sistema nervioso central.
ES2290774T3 (es) Uso de 1,3-diaza-dibenzo(e,h)azulenos para la fabricacion de formulaciones farmaceuticas para el tratamiento y prevencion de enfermades y transtornos del sistema nervioso central.
US20070173499A1 (en) Use of benzonaphthoazulenes for the manufacture of pharmaceutical formulations for the treatment and prevention of central nervous system diseases and disorders
US20070111968A1 (en) 1-Aza-dibenzo[e,h]azulenes for the treatment of central nervous system diseases and disorders
HK1098670B (en) Use of 3-aza-1-oxa-dibenzo [e,h] azulenes for the manufacture of pharmaceutical formulations for the treatment and prevention of central nervous system disease and disorders
HK1098668B (en) Use of 1,3-diaza-dibenzo [e,h] azulenes for the manufacture of pharmaceutical formulations for the treatment and prevention of central nervous system diseases and disorders